NVDA 155.46 ▼0.44%GOOGL 280.20 ▼1.24%MSFT 506.24 ▼2.27%AMD 503.41 ▼0.17%INTC 55.17 ▼0.54%TSMC 359.69 ▼3.68%AMZN 257.89 ▲0.05%META 618.87 ▼1.20%AAPL 351.91 ▼0.25%PLTR 156.56 ▼2.39%
Markets at last close

Anthropic · Health

Anthropic expands into drug discovery and laboratory research

·1 min read

Anthropic is expanding its biomedical business beyond research assistance into early drug discovery, combining Claude-based software, laboratory infrastructure and acquired biotech capabilities. Its stated goal is to let scientists delegate complex research tasks rather than use AI only for individual steps. Drug development also offers a potential route toward outcome-based payments tied to valuable research milestones.

Claude Science brings literature retrieval, data analysis and scientific writing into a shared workspace connected to specialist databases and tools. The company’s Model Hardware Standard aims to give laboratory instruments a common interface, allowing AI systems to discover equipment, read its status and request operations. Anthropic also operates an internal wet laboratory and works with external facilities, although human scientists still perform experimental operations in its biology research team.

Acquisitions of Coefficient Bio and Mithril Medicine have added specialist talent and internal drug programs, including rare-disease antibody research. Anthropic says its own development work will stop before human trials and prioritize conditions underserved by commercial investment, helping limit conflicts with pharmaceutical customers. Physical experimentation remains a bottleneck as computational molecular design accelerates, making reliable laboratory feedback central to improving its models and research workflows.

Originally reported by eu.36kr.comRead the source →
Related coverage
All Anthropic news →